Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)
- Conditions
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Interventions
- Biological: Tisagenlecleucel
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04456023
A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT04452877
- Locations
- 🇨🇳
Novartis Investigative Site, Shanghai, China
Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD)
- First Posted Date
- 2020-06-23
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 5
- Registration Number
- NCT04443907
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Memorial Sloan Kettering Cancer Ctr, New York, New York, United States
🇺🇸St Jude Children's Research Hospital, Memphis, Tennessee, United States
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 22
- Registration Number
- NCT04427072
- Locations
- 🇻🇳
Novartis Investigative Site, Hanoi, Vietnam
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 134
- Registration Number
- NCT04417621
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 335
- Registration Number
- NCT04410523
- Locations
- 🇸🇰
Novartis Investigative Site, Presov, Slovakia
The Purpose of This Study is to Investigate Safety and Tolerability of Tropifexor.
- Conditions
- Liver Disease
- Interventions
- Drug: triopifexorDrug: Placebo
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 89
- Registration Number
- NCT04408937
- Locations
- 🇺🇸
Novartis Investigative Site, San Antonio, Texas, United States
Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Subjects With Bronchiectasis
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 42
- Registration Number
- NCT04396366
- Locations
- 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom
Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2020-05-18
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 164
- Registration Number
- NCT04390763
- Locations
- 🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Univ of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease
- First Posted Date
- 2020-05-18
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 718
- Registration Number
- NCT04391894
- Locations
- 🇺🇸
Arizona Eye Center, Chandler, Arizona, United States
🇺🇸Carrot Eye Center, Mesa, Arizona, United States
🇺🇸Lee Shettle Eye & Hearing, Largo, Florida, United States